Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Outlook Therapeutics, Inc.

https://outlooktherapeutics.com

Latest From Outlook Therapeutics, Inc.

Keeping Track: Gilead Gets CRL For Bulevirtide, CytoDyn Withdraws Leronlimab; Eye and CNS Drug Submissions

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

US FDA Performance Tracker Drug Review

Outlook Refiles Ophthalmic Bevacizumab In US

Outlook Therapeutics has confirmed the re-submission of its proposed ophthalmic bevacizumab with the US Food and Drug Administration, after the agency requested further information.

Biosimilars Regulation

Outlook Eyes Blockbuster-Sized Sales For An Old Eye Drug In Wet-AMD

The company is seeking FDA approval for a first-time ophthalmic formulation of bevacizumab and also refiled its BLA.

Ophthalmic Business Strategies

Outlook Pulls Bevacizumab BLA As Filing Falls Short

Pinning its hopes on its proposed bevacizumab product for ophthalmic indications, Outlook Therapeutics has been told to give more information to the US FDA ahead of an approval. However, one analyst remained upbeat for the company’s prospects.

Regulation Strategy
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • Oncobiologics, Inc.
UsernamePublicRestriction

Register